Hims & Hers Health, Inc. Class A Common Stock (HIMS)

New products are coming to the Hers platform.

The rally followed BofA Securities’ announcement that the new menopause and perimenopause service represents a multi-billion-dollar market opportunity for HIMS, supporting revenue diversification.

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.

Investors liked what they heard about the company's latest expansion of its business.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 5.7% in the afternoon session after the company announced the launch of perimenopause and menopause treatment options on its platform. This expansion into women's health offered customers access to personalized treatment plans and prescription medications, including estradiol and progesterone. The treatments were made available in various forms such as pills, patches, and creams. The move was seen as a significant step for the company, which was reportedly on a path to achieve over $1 billion in annual revenue by 2026. By adding these hormone-replacement therapies, Hims & Hers broadened its services for its large subscriber base.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company's launch of a new menopause and perimenopause care specialty on its Hers platform.

Shares are nearing a buy point out of a cup-with-handle base.

Investors looking at the healthcare industry have two excellent choices with UnitedHealth and Hims & Hers.

Discover how Hims & Hers Health (HIMS) combines explosive revenue growth with a bullish technical setup, making it a top telehealth stock to watch.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue forecast. 

HIMS stock shows strong technical momentum and a consolidation pattern, suggesting a potential breakout. The setup offers a clear risk/reward profile for technical traders.

Investors generally aren't fond of C-suite changes in relatively young businesses.

Hims & Hers (HIMS) is a high-growth momentum stock with strong earnings and a positive technical breakout setup, offering a compelling opportunity for investors.

A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. 

These innovators are disrupting massive industries with a customer-centric business strategy.

The year 2025 has unfolded with a compelling narrative of unexpected triumphs in the stock market, where several companies have defied conventional wisdom and analyst forecasts to emerge as significant outperformers. These "surprise winners" underscore the dynamic and often unpredictable nature of financial markets, highlighting that substantial returns can spring

The company has multiple trends working in its favor.

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).